

### The Amendments

Claim 1 is amended to correct a typographical error and to clarify the meaning of “reduced.”

Claim 6 is amended to clarify the intended meaning. This is supported at page 26, lines 16-19 which describes the culturing of transfected cells to synthesize the immunoconjugate.

Claim 13 was amended to recite a single member of the Markush group. Other members are recited in new claims 35, 36, and 38.

Claim 17 is amended to include a double-mutant as taught at page 11, lines 19-22.

Claim 20 is amended to render it independent and to have the same scope as claim 17 as amended.

New claims 25-34 are similar to original claims 1, 6, 9, 14, 17, 19, 21, 22, 23, and 24, respectively. However, the targeting domain of the immunoconjugates in the new claims recite specific targeting of human tumor cells or tumor vasculature. This is supported at page 13, lines 26-30, which teaches an immunoconjugate comprising “a targeting domain that specifically targets human tumor cells or tumor vasculature endothelial cells.” Moreover, the new claims recite that the immunoconjugate does not comprise an ScVv, or a V<sub>H</sub>. This is supported at page 5, lines 18-19 and 29-30.

New claims 29-45 are directed to expression vectors. Such vectors are disclosed *inter alia* at page 123, lines 25-33.

New claim 46 recites the double mutant protein as taught at page 11, lines 19-22.


New claims 47, 48, and 50, are like original claims 1 and 9, however, they do not require mutants of factor VII that have reduced coagulation activity. This is supported at page 11, lines 11-14, which teaches that such mutants are employed in preferred embodiments of the invention.

New claim 50 is like claim 48 but recites administration of an expression vector. The expression vector is disclosed at page 12, last paragraph.

New claim 49 is supported by original claims 13, 10, and 11, and throughout the specification.

No new matter has been added. Examination of all claims is respectfully requested. The additional claim fees accompany this amendment.

Respectfully submitted,

  
Sarah A. Kagan  
Reg. No. 32,141

Dated: September 29, 2003

Banner & Witcoff, Ltd.  
Customer No. 22907